Arcus Biosciences, Inc. announced a private placement of 15,238,096 common shares at a price of $21 per share for the gross proceeds of $320,000,016 on January 29, 2024. The transaction will include participation from returning investor Gilead Sciences, Inc. for 33% stake.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.44 USD | -0.39% | +4.85% | -19.14% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
65.19 USD | -0.49% | 0.00% | 81.69B | ||
15.44 USD | -0.39% | +4.85% | 1.41B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.14% | 1.41B | |
+19.87% | 42.68B | |
-2.60% | 42.4B | |
+45.04% | 40.04B | |
-6.20% | 28.31B | |
+6.93% | 24.94B | |
-20.82% | 18.96B | |
+30.20% | 12.3B | |
-2.50% | 11.95B | |
-2.97% | 11.55B |
- Stock Market
- Equities
- RCUS Stock
- News Arcus Biosciences, Inc.
- Arcus Biosciences, Inc. announced that it expects to receive $320.000016 million in funding from Gilead Sciences, Inc.